Akershus Cardiac Examination 4 Study — ACE4  

Heart Failure Clinical Trial

Official title: Akershus Cardiac Examination (ACE) 4 Study: Pragmatic Randomized Controlled Trial of Early Biomarker Measurements and Structured Feedback in Unselected Patients With Tachypnea

Status Recruiting

Clinical Trial Summary

Patients hospitalized with tachypnea, defined as respiratory rate ≥20/ min, have substantial mortality and may suffer from different conditions, including acute heart failure (HF). Symptoms of HF can be difficult to identify and ~15% of patients with HF will not be correctly diagnosed by the treating physician in the Emergency Department. Biomarkers like B-type natriuretic peptides and cardiac troponins improve diagnostic accuracy and risk stratification. Whether early, structured biomarker assessment and structured feedback in the patient's electronic health records improve management and outcomes among unselected patients with tachypnea have previously not been explored in a randomized controlled trial. The main research question of the study is to determine whether early structured biomarker assessment in unselected patients with tachypnea extends the time to the first event for either (1) all-cause readmission or (2) all-cause mortality; i.e. time to the combined endpoint, compared to the current strategy/standard care

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Heart Failure
• Tachypnea

• NCT number: NCT05699564
• Study type: Interventional
• Source: University Hospital, Akershus
• Contact: Magnus N Lyngbakken, MD PhD
• Phone: +4793408837
• Email: magnus.lyngbakken@medisin.uio.no
• Status: Recruiting
• Phase: N/A
• Start date: March 3, 2023
• Completion date: December 2038